Kiniksa Pharmaceuticals, Ltd. KNSA
$ 22.59
-1.83%
Quarterly report 2024-Q3
added 10-29-2024
Kiniksa Pharmaceuticals, Ltd. Balance Sheet 2011-2024 | KNSA
Annual Balance Sheet Kiniksa Pharmaceuticals, Ltd.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-95.7 M | -117 M | -116 M | -107 M | -46.9 M | -72 M | -45.6 M | -56 M | - | - | - | - | - |
Long Term Debt |
10 M | 2.62 M | 2.67 M | 4.88 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
2.25 M | 3.3 M | 3.38 M | 2.11 M | 1.7 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 1.28 M | 144 K | 120 M | 79.9 M | - | - | - | - | - |
Total Current Liabilities |
63.7 M | 47.1 M | 44.8 M | 31.8 M | 27.8 M | 42.6 M | - | - | - | - | - | - | - |
Total Liabilities |
87.5 M | 63.5 M | 47.8 M | 37.5 M | 29.1 M | 42.7 M | 137 M | 82.2 M | - | - | - | - | - |
Deferred Revenue |
307 K | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-478 M | -492 M | -675 M | -517 M | -356 M | -194 M | -91 M | -26.1 M | - | - | - | - | - |
Total Assets |
526 M | 460 M | 233 M | 349 M | 255 M | 322 M | 47.5 M | 56.5 M | - | - | - | - | - |
Cash and Cash Equivalents |
108 M | 123 M | 122 M | 114 M | 46.9 M | 72 M | 45.7 M | - | - | - | - | - | - |
Book Value |
439 M | 396 M | 185 M | 312 M | 225 M | 279 M | -89.7 M | -25.7 M | - | - | - | - | - |
Total Shareholders Equity |
439 M | 396 M | 185 M | 312 M | 225 M | 279 M | -89.7 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Kiniksa Pharmaceuticals, Ltd.
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
8.56 M | 9.32 M | 9.86 M | 10.7 M | 11.3 M | 2.13 M | 2.62 M | 3.44 M | - | 2.1 M | 2.67 M | 3.5 M | 3.5 M | 4.2 M | 4.88 M | 4.88 M | 4.88 M | 4.88 M | 955 K | 955 K | 955 K | 955 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
118 M | 107 M | 87.8 M | 77.9 M | 72.7 M | 52.8 M | 63.5 M | 75.9 M | - | 64.7 M | 47.8 M | 38.8 M | 43.4 M | 40.5 M | 37.5 M | 37.5 M | 37.5 M | 37.5 M | 29.1 M | 29.1 M | 29.1 M | 29.1 M | 42.7 M | 42.7 M | 42.7 M | 42.7 M | 17.4 M | 17.4 M | 17.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | 12 K | 156 K | 2.56 M | 4.67 M | 6.5 M | - | 12.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-512 M | -500 M | -496 M | -503 M | -489 M | -504 M | -492 M | -496 M | - | -701 M | -675 M | -639 M | -609 M | -567 M | -517 M | -517 M | -517 M | -517 M | -356 M | -356 M | -356 M | -356 M | -194 M | -194 M | -194 M | -194 M | -91 M | -91 M | -91 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
555 M | 542 M | 520 M | 483 M | 484 M | 443 M | 460 M | 460 M | - | 231 M | 233 M | 253 M | 279 M | 311 M | 349 M | 349 M | 349 M | 349 M | 255 M | 255 M | 255 M | 255 M | 322 M | 322 M | 322 M | 322 M | 47.5 M | 47.5 M | 47.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
97.4 M | 99.3 M | 141 M | 118 M | 113 M | 80.6 M | 123 M | 176 M | 94.3 M | 63.3 M | 122 M | 190 M | 168 M | 120 M | 114 M | 114 M | 114 M | 114 M | 46.9 M | 46.9 M | 46.9 M | 46.9 M | 72 M | 72 M | 72 M | 72 M | 45.6 M | 45.6 M | 45.6 M | - | 56.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
437 M | 435 M | 432 M | 405 M | 412 M | 390 M | 396 M | 384 M | - | 166 M | 185 M | 214 M | 236 M | 271 M | 312 M | 312 M | 312 M | 312 M | 225 M | 225 M | 225 M | 225 M | 279 M | 279 M | 279 M | 279 M | 30.1 M | 30.1 M | 30.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
437 M | 435 M | 432 M | 405 M | 412 M | 390 M | 396 M | 384 M | 153 M | 166 M | 185 M | 214 M | 236 M | 271 M | 312 M | 312 M | 312 M | 312 M | 225 M | 225 M | 225 M | 225 M | 279 M | 279 M | 279 M | 279 M | -89.7 M | -89.7 M | -89.7 M | - | -25.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency